Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.

Objective: To report COVID-19 rates in pwMS according to vaccine serology.

Methods: PwMS with available (1) serology 2-12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included.

Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.

Background: Dimethyl fumarate (DMF) is a disease modifying therapy (DMT) used in the management of Multiple Sclerosis (MS). Lymphopenia occurs in approximately 30% of people receiving this medication. The recently revised Summary of Product Characteristics (SPC) recommends increased monitoring or cessation of this medication in the context of persistent lymphopenia, because of an increased risk of progressive multifocal leukoencephalopathy (PML).

Cyanoacrylate microbial sealants for skin preparation prior to surgery.

Background: Surgical site infections (i.e. incisions that become infected) are a continuing concern in health care.